PSMA-11

Phase 2Small molecule

NNational Cancer Institute (NCI)

PSMA-11 is one of 25 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate NeoplasmsActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Prostate NeoplasmsPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

PSMA-11

NNational Cancer Institute (NCI)

Phase 2

3 5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Duragesic

CCephalon

Preclinical

1 7

Ifex

BBaxter Healthcare Corporation

Xylocaine

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—10

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Active, not recruiting

Prostate Neoplasms

NCT03181867

Clinical

Trials by Indication[1]

Magnetic Resonance Imaging1 trial

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Completed·IIrene Burger·N/A·NCT03187990·52 enrolled

mCRPC1 trial

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

No longer available·AAdvanced Accelerator Applications··NCT04825652

Prostate Neoplasms1 trial

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03181867·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PSMA-11. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PSMA-11 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PSMA-11. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

PSMA-11

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Magnetic Resonance Imaging1 trial

mCRPC1 trial

Prostate Neoplasms1 trial

References

Drug Info

Quick Facts

Related News